Time matters
A call to prioritize brain health

Alastair Noyce
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK

Preparation of the *Time matters* report and supporting materials has been funded by grants from Biogen and F. Hoffmann-La Roche, who had no influence on the content.
Why does time matter?

Misunderstanding
Brain diseases are generally regarded as a problem for the elderly, but neurodegeneration begins in middle age.

Change
There is a window of opportunity to make changes earlier, to reduce risk and prevent or delay the onset of symptoms.

Growing burden
These diseases are growing at an alarming rate and we are poorly prepared to deal with this.

Communication
General awareness and dialogue must grow. Disruption in this area could help stem the rising tide.
How was the report developed?

An expert group developed **evidence-based recommendations** and a **call to action** encouraging positive behaviour change and policies to promote brain health, working towards the prevention of neurodegenerative diseases.
A call to action!

Each of us needs to act now to prioritize brain health

**Behaviour change**
The report highlights the need to prioritize the health of your brain and to implement behaviours that reduce the risks as you age.

**Education**
Policymakers, public health bodies and health professionals must educate and empower the public.

**Research**
Funding is needed to research the processes, markers and interventions in the earliest phases.

**Health checks**
Programmes to detect disease early or ‘brain health checks’ could be introduced in the future.
The message “what’s good for your heart is generally good for your brain” needs to be widely communicated and understood.

Further work is needed to validate diagnostic and early detection tools to identify people at risk and to develop effective treatments and interventions.

Example recommendations:

- Provide a supportive environment, including guidance and legislation that empowers people to make important lifestyle changes.
- Prepare for the likely growth in the demand for genetic testing from people who want to understand more about their own risk.
- Assess the relative weight of different risk factors and the interactions between them, so that they can be prioritized.
- Develop, validate and approve tests, tools and apps to monitor brain health.
We are proud to have received the following 8 endorsements and would welcome endorsement from other stakeholder groups.

Thank you to our endorsers!
Who are the authors?

**Writing group**
- Professor Gavin Giovannoni (Chair)
- Dr Alastair Noyce (Co-chair)
- Professor Philip Scheltens (Co-chair)
- Professor Daniela Berg
- Professor Laurie Berg
- Professor Kris Dierickx
- Professor Giovanni Frisoni
- Mr Jean Georges
- Professor John Hardy
- Dr Karl Heilbron

**Working group**
- Professor David Dexter
- Professor John Gallacher
- Ms Ingrid Roesner
- Professor Monica Di Luca
- Dr Hilary Evans
- Ms Ruth Trout
- Ms Lizzie Graham
- Ms Susanna Lindvall
- Dr Charlotte Warren-Gash
- Professor Jan de Lepeleire
Speak to us today to find out more!

Or email: ruth.bentley@oxfordhealthpolicyforum.org
Alastair Noyce has received the following:

- Grants
  - Preventive Neurology Unit (Barts Charity)
  - PREDICT-PD (Parkinson’s UK)
  - PREDICT-PD: MRI (Leonard Wolfson Experimental Neurology Centre)
  - East London PD Project (Virginia Kieley Benefaction)

- Consultancy fees
  - Britannia Pharmaceuticals
  - Global Kinetics Corporation
  - Profile Pharmaceuticals
  - Bial Pharmaceuticals
  - Biogen
  - F. Hoffmann-La Roche

The authors acknowledge the expertise of Dr Nick Fahy, University of Oxford, in providing guidance about policy recommendations and processes.